The New Techno-Eugenics: Germline Engineering and the End of Humanity
By Dan Cloer,
Vision [cites CGS' Richard Hayes]
| 07. 16. 2019
Our newfound power to manipulate the genes of our children compels the human community to address a foundational question: Will we use science and technology to further or to subvert the human species?
Fifteen thousand babies are born every hour, every day, around the world. About 3 percent, or 450 individuals, are twins. In November 2018, a very special set of twins were born in China. Named Nana and Lulu, the sisters were the first humans to be genetically altered using CRISPR, the gene-editing system developed from bacteria.
A codiscoverer and pioneer in the application of CRISPR technology to genome editing, Berkeley scientist Jennifer Doudna, told Vision in 2016, “The big-picture view is that we have the tools to change our DNA and change the things that we are passing on to future generations. And now we can make those decisions. That is a profound thought.”
Continuing, Doudna noted general agreement among the scientific community that there should be “broad societal consensus before we use this technology in any clinical application in the human germline. But how do you define ‘broad societal consensus’? That remains to be seen; it was not the end of the conversation but the beginning.”
But conversation and consensus have been overwhelmed by the reality of Nana and...
Related Articles
By David Jensen, The California Stem Cell Report | 03.26.2026
SACRAMENTO, Ca. -- California’s $12 billion stem cell and gene therapy program scored a historic first today, announcing that it had for the first time helped to finance a revolutionary treatment that will now be available to the general public...
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
By Darren Incorvaia, Fierce Biotech | 03.11.2026
A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way for the next generation of gene editing medicines.
The approach, which is described in a Nature paper...